ORPHA:3226
Deafness-lymphedema-leukemia syndrome
Also known as: Emberger syndrome · Hearing loss-lymphedema-leukemia syndrome
Publications
16,378
Trials
0
Interventional, condition-specific
Researchers
1,222
Distinct authors in sample
Gene link
GATA2
Definitive
Readiness
3/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013540
- OMIM:614038
- UMLS:C3279664
Additional Mondo synonyms (1)
deafness-lymphedema-leukemia syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — GATA2
- LiteraturePresent
16,378 matched papers (11,262 in last 10 years) Source
- Phenotype characterisedPresent
13 HPO annotations (e.g. Hypotelorism; Webbed neck; Epicanthus) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GATA2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
13
Associated phenotypes · MONDO:0013540
- Hypotelorism
- Webbed neck
- Epicanthus
- Long fingers
- Verrucae
Showing 5 of 13 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
16,378
16,378 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
16,378 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
11,262 in the last 10 years · low confidence
Phrase hits: 284 · MeSH hits: 0
Who's working on it?
1,222
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Holland SM17 papers · 2024
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Papers in Europe PMC - 02Hsu AP13 papers · 2022
Laboratorie of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases.
Papers in Europe PMC - 03Mansour S11 papers · 2024
Lymphovascular Research Unit, Molecular and Clinical Sciences Research Institute, University of London St George's, London, UK smansour@sgul.ac.uk.
Papers in Europe PMC - 04Calvo KR9 papers · 2023
Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda.
Papers in Europe PMC - 05Hickstein DD9 papers · 2024
Experimental Transplantation and Immunology, National Cancer Institute, National Institutes of Health, Bethesda, MD;
Papers in Europe PMC - 06Ostergaard P8 papers · 2024
Lymphovascular Research Unit, Molecular and Clinical Sciences Institute, St George's University of London, SW170RE, London, UK.
Papers in Europe PMC - 07Zerbe CS7 papers · 2024
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Papers in Europe PMC - 08Abraham RS6 papers · 2025
Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Papers in Europe PMC - 09Hahn CN6 papers · 2024
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Papers in Europe PMC - 10McReynolds LJ6 papers · 2024
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03050268·RECRUITING·Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia · Adenomatous Polyposis · Adrenocortical Carcinoma · AML·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Deafness-lymphedema-leukemia syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Deafness-lymphedema-leukemia syndrome" OR "Emberger syndrome" OR "Hearing loss-lymphedema-leukemia syndrome") OR ("GATA2" OR "GATA2 syndrome" OR "GATA2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Deafness-lymphedema-leukemia syndrome" OR "Emberger syndrome" OR "Hearing loss-lymphedema-leukemia syndrome"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (16378) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T22:33:29.420Z